Global Legal Status

Psilocybin mushrooms never specifically scheduled under Dangerous Drugs Act. Health Ministry has warned against unregulated products (2024). Calls to amend law to regulate use. UWI partnered with Canadian company for research. No pending legislation to restrict.

Psilocybin and psilocybin mushrooms are not listed as controlled substances. Operates in legal limbo with no explicit prohibition. Growing market operates unchecked. No specific regulations or pending legislation to schedule or formalize access.

Magic mushrooms are not listed in Nepal's Narcotic Drugs Control Act. Effectively unregulated with open sale and use permitted. No pending legislation to restrict or formalize access.

Psilocybin truffles (sclerotia) legal and sold in smartshops under Dutch Commodities Act (food safety law). Dried mushrooms banned since 2008 but truffles exempted due to legal technicality. No pending changes to truffle legality.

Psilocybin and MDMA rescheduled from Schedule 9 to Schedule 8 (controlled medicines) in July 2023. Only authorized psychiatrists can prescribe for treatment-resistant depression. New quality standards (TGOs) effective January 2025. Medibank began covering treatments in 2025.

Special Access Program (SAP) amended in January 2022 to allow physician requests for psilocybin. Health Canada has authorized 301 requests total (56 in 2022, 106 in 2023, 104 in 2024, 35+ in 2025). Some decline in approval rates noted in 2025.

Access through federal Special Access Program. Alberta-based clinics operating under SAP guidelines. No provincial-specific legislation pending.

Limited medical use program since 2014 allows authorized physicians to treat with MDMA, LSD, and psilocybin under strict oversight. By 2024, over 700 patients treated for depression, PTSD, and anxiety. One of Europe's only active psychedelic treatment programs.

Measure 109 passed Nov 2020. Oregon Psilocybin Services Act launched Jan 2023. Rule revisions effective Jan 1, 2025. HB 2387 signed in 2025 allowing health care providers to discuss and provide services. Over 10,000 clients served as of 2025.

Proposition 122 (Natural Medicine Health Act) passed Nov 2022. Decriminalized personal use/possession for adults 21+. Facilitator licensing opened Dec 2024. First state-regulated psilocybin session held June 6, 2025. DMT, ibogaine, mescaline may be added later.

Senate Bill 219 (Medical Psilocybin Act) signed April 7, 2025. Third state to legalize, first to do so legislatively (not ballot). Takes effect June 20, 2025. Program launch expected by end of Dec 2026. Dept of Health initiating rulemaking.

Ordinance 301 passed May 2019, making Denver first US city to decriminalize psilocybin. Makes enforcement lowest law enforcement priority. Now superseded by statewide Prop 122 for broader access.

Resolution passed June 2019 making investigation/arrest for adult use of entheogenic plants lowest priority. Covers psilocybin, ayahuasca, iboga, mescaline. No state-level legislation pending in California as of 2025.

Initiative 81 passed Nov 2020 with 76% approval. Makes entheogenic plants/fungi lowest law enforcement priority. Covers psilocybin, ayahuasca, iboga, mescaline. No further legislation pending.

City Council resolution passed Oct 2021 making psilocybin, ayahuasca, ibogaine lowest law enforcement priority. Washington state considering broader access but no legislation passed as of 2025.

City Council resolution passed Jan 2020 making entheogenic plants/fungi lowest law enforcement priority. Second US city after Oakland to decriminalize. No state legislation pending.

All drugs decriminalized for personal use since 2001 (Law 30/2000). Possession of small amounts treated as administrative offense, not criminal. Sale/distribution still illegal. Model focused on harm reduction and treatment. No changes to policy pending.

Traditional/indigenous use of psilocybin protected. Supreme Court analyzing prohibition of psilocybin practices and human rights impact (case first debated 2024, reconsidered 2025). Potential for broader access depending on court ruling.

Personal use not criminalized but production/sale illegal. Some legal retreats operate. Growing debate on revising psychedelic legislation but currently illegal and inaccessible for medical use. No pending legislation for therapeutic access.

Traditional use of Bufo alvarius (Sonoran Desert Toad) venom containing 5-MeO-DMT protected for indigenous ceremonies. Conservation concerns due to over-harvesting. Supreme Court case may impact broader access.

5-MeO-DMT not specifically scheduled. Personal use tolerated but sale/distribution illegal. Some ceremonial use occurs. No specific legislation pending.

Covered under Portugal's 2001 decriminalization of all drugs for personal use. Possession treated as administrative offense. Part of harm reduction approach.

Medical psilocybin legalized in June 2025, taking effect January 1, 2026. First EU country to legalize medical psilocybin. Only certified psychiatrists with psychedelic therapy training may administer synthetic psilocybin. Health insurers required to cover treatments.

Psilocybin and ayahuasca operate in a legal gray zone. Not explicitly prohibited under law, though personal drug use is not prosecuted. Many retreat centers operate openly. No specific regulations or pending legislation for psychedelics.

Compassionate Use Programme approved July 11, 2025 by Federal Institute for Drugs and Medical Devices. First EU country to allow legal psilocybin access outside clinical trials. Two medical facilities authorized to treat adults with treatment-resistant depression.

Psilocybin and other psychedelics illegal. Ketamine only legally available psychedelic for therapy. Underground use reportedly rising (2025 European Drug Report). Medical cannabis made permanent April 2025, but no psychedelic legislation pending.

Psychedelics classified as illicit drugs. Finnish Association for Psychedelic Research active. Naturalistic use growing but no therapeutic access or legislation pending.

Magic mushrooms explicitly outlawed under narcotic regulations. Proposed decriminalization model would allow 50g magic mushrooms for personal use, but bill has not passed. No therapeutic access.

Psilocybin mushrooms listed as narcotic since June 1966. No authorized therapeutic use. No pending legislation for psychedelic access. Research limited.

Psychedelics classified as substances with no recognized medical use and high abuse potential. No criminal penalties for possession but administrative penalties may apply. No legislation pending for therapeutic access.

Mushroom cultivation prohibited since Criminal Law of February 25, 1921. One of Europe's most restrictive frameworks for psychedelics. No pending legislation for therapeutic or decriminalized access.

Zero-tolerance drug policy. LSD, MDMA, and psilocybin all illegal. Spores and grow kits technically legal but use is prohibited. No reform expected given strict policy stance.

Standard prohibition applies. Psilocybin classified as controlled substance. No specific legislation or reform pending for therapeutic or decriminalized access.

Psilocybin banned under controlled substances law. Wild-growing mushrooms not specifically controlled, creating gray area. No legislation pending for therapeutic or decriminalized access.

Both psilocybin and mushrooms explicitly banned under Narcotic Drugs and Psychotropic Substances Act. However, possession for personal use is decriminalized (fines apply). No therapeutic access or reform pending.

Psilocybin and mushrooms classified as controlled substances. Standard prohibition applies. No specific legislation or reform pending for therapeutic or decriminalized access.

Growing prohibited under Art. 265 of Penal Code. Possession and sale illegal under Administrative and Penal codes. No legislation pending for therapeutic or decriminalized access.